A study published recently by top medical journal, the British Medical Journal shows that a popular birth control drug marketed to women known as “Depo,” has been shown to be associated with elevated risk of brain tumor called intracranial meningioma.
Pfizer, the manufacturer of Depo-Provera, has had to publicly disclose numerous problems with the drug, including its association with the following:
MEDIA LIES, WOMEN DIE
A decade ago, affluent white liberal women shrieked bloody murder when it was suggested that birth control caused cancer. We mostly have Oprah to blame for that.
This was largely because media shills like ABC ran headlines like “Oral Contraceptives May Decrease Death Risk, Researchers Say“.
A website calling itself “The Conversation,” which claims “academic rigor” in its slogan, called the idea that “the pill increases your risk of cancer” a “medical myth.”
A rag calling itself the “New Scientist” even advocated putting nuns on the pill to protect against cancer — this at a time when research showed that the pill CAUSED cancer.
This despite the fact that the NIH had already published research in 2010 that showed that oral contraceptives elevated the risk of breast cancer.
NBC even reported in 2012 that Depo-Provera birth control shots elevated women’s risk of breast cancer.
The news was widely available, and clearly showed that all-cancer risk rose with use of oral contraceptives, as the NIH reported.
Canadian Dr. Chris Kahlenborn’s published a 2007 study showing that women on the Pill before having their first child have a 44% increased risk in breast cancer.
Even VOGUE Magazine was eventually forced to admit that IUDs cause cancer.
But now, ten years later, in an increasingly discerning post-covid health care market, the reality that birth control causes cancer has finally sunk in.
The National Institutes of Health reports that “studies have provided consistent evidence that the risks of breast and cervical cancers are increased in women who use oral contraceptives.”
DEPO-PROVERA SOUNDS SO … INNOCENT
Depo contains the hormone progestin, and prevents ovum in fertile females from releasing an egg to be fertilized.
Depo, which stands for Depo-Provera, is the fourth most prescribed birth control on the planet, with nearly one hundred million users. More than one in five sexually active American woman report having used Depo-Provera.
Depo-Provera can be taken by injection or orally in pill form.
Pfizer, which rushed the so-called mRNA “vaccine” through Emergency Use Authorization beginning in 2020, is the manufacturer of Depo-Provera.
Many observers have called Pfizer’s mRNA Covid therapy a bioweapon.
French researchers reported in the recent study published in The BMJ that medrogestone, promegestone, and injectable medroxyprogesterone acetate—a widely used contraceptive known by the brand name Depo-Provera—increase the risk of intracranial meningiomas, many of which require surgery.
A group of French researchers — Noémie Roland, Lise Duranteau, Mahmoud Zureik, Alain Weill, Léa Hoisnard, Anke Neumann, and Sébastien Froelich — which include epidemiologists, a neurosurgeon, and an endocrinologist, examined French national health data for women who underwent surgery for intracranial meningioma between Jan. 1, 2009, and Dec. 31, 2018.
The researchers used data from the French national health data system for women of all ages who underwent surgery for intracranial meningioma between Jan. 1, 2009, and Dec. 31, 2018, to determine whether progestogens increased the risk of developing meningiomas.
Epoch Times investigative reporter Megan Redshaw reports:
The link between female sex hormones—namely progesterone and intracranial meningioma—is “biologically plausible,” as 60 percent of meningiomas have progesterone receptors, and the magnitude of these tumors appears to increase during pregnancy, when progesterone levels are elevated, and decrease postpartum. Additionally, studies have suggested a link between breast cancer and meningiomas.
According to the authors of the BMJ study, the incidence of meningiomas attributable to Depo-Provera and the progestogen found in it may be “potentially high” in countries with a high use rate of contraceptive.
The anti-birth pharmaceutical industry has had to adapt as cancer incidence has continued to rise.
As of 2019, about one-quarter (24%) of women ages 15-44 who currently use contraception reported using the pill as their method of choice, a decline from 31% in 2002, according to the Kaiser Family Foundation.
Approximately 14% of American women of reproductive age use the contraceptive pill, while another 10% use LARCs such as Depo-Provera or implants.
